MD5

MD5 is a selective TMPRSS6 mimetic peptide inhibitor with an IC50 for recombinant human TMPRSS6 protein of 22 nM and a Ki of 3.4 nM. MD5 exhibits the significantly reduced inhibitory effect on Matriptase, with an IC50 of 352 nM and a Ki of 99.2 nM. MD5 exhibits good target specificity and only has a weak inhibitory effect on thrombin (Thrombin), with Ki of 120 nM. MD5 demonstrates good initial drugability and can be used for the study of iron overload diseases (such as hereditary hemochromatosis, β-thalassemia) [1].

3051556-89-6

12352209

Ser/Thr Protease; Thrombin

Metabolic Enzyme/Protease

Metabolism-protein/nucleotide metabolism

Metabolic Disease

O=C([C@@H](NC([C@@H](NC([C@@H](NC(CCC1=CC=CC=C1)=O)CC2=CSC=N2)=O)C3CCCCC3)=O)CCCNC(N)=N)C4=NC5=C(S4)C=CC=C5

C36H44N8O4S2

716.92

[1]Desgagné M, et al. Rational In Silico Design of Selective TMPRSS6 Peptidomimetic Inhibitors via Exploitation of the S2 Subpocket. J Med Chem. 2024 Aug 8;67 (15) :12969-12983.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11260/

Peptides

No Development Reported